Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:HRMY NASDAQ:TRVI NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.86+2.5%$4.03$1.23▼$4.98$490.32M1.83894,781 shs2.62 million shsHRMYHarmony Biosciences$32.78+1.4%$28.83$25.52▼$40.87$1.90B0.97865,478 shs748,905 shsTRVITrevi Therapeutics$14.26-2.7%$12.57$5.38▼$16.12$1.83B1.071.50 million shs1.73 million shsVCELVericel$36.78-0.1%$34.02$28.95▼$45.97$1.87B1.15583,100 shs828,608 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-2.09%-0.03%-1.31%-8.19%+165.37%HRMYHarmony Biosciences+1.60%+3.79%+16.58%-13.34%+7.94%TRVITrevi Therapeutics+5.70%+6.12%+22.78%+28.03%+112.46%VCELVericel+3.49%+3.25%+7.82%-0.19%-6.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.86+2.5%$4.03$1.23▼$4.98$490.32M1.83894,781 shs2.62 million shsHRMYHarmony Biosciences$32.78+1.4%$28.83$25.52▼$40.87$1.90B0.97865,478 shs748,905 shsTRVITrevi Therapeutics$14.26-2.7%$12.57$5.38▼$16.12$1.83B1.071.50 million shs1.73 million shsVCELVericel$36.78-0.1%$34.02$28.95▼$45.97$1.87B1.15583,100 shs828,608 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-2.09%-0.03%-1.31%-8.19%+165.37%HRMYHarmony Biosciences+1.60%+3.79%+16.58%-13.34%+7.94%TRVITrevi Therapeutics+5.70%+6.12%+22.78%+28.03%+112.46%VCELVericel+3.49%+3.25%+7.82%-0.19%-6.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 2.50Moderate Buy$8.00107.52% UpsideHRMYHarmony Biosciences 2.42Hold$42.6730.16% UpsideTRVITrevi Therapeutics 3.00Buy$21.7052.17% UpsideVCELVericel 2.63Moderate Buy$55.4050.63% UpsideCurrent Analyst Ratings BreakdownLatest ADCT, HRMY, TRVI, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026TRVITrevi Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.005/6/2026TRVITrevi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.005/6/2026TRVITrevi Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $23.005/5/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.005/5/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/1/2026HRMYHarmony Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026HRMYHarmony Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/20/2026ADCTADC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026TRVITrevi Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026TRVITrevi Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.004/15/2026VCELVericel Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$48.00 ➝ $42.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$81.36M6.03N/AN/A($1.50) per share-2.57HRMYHarmony Biosciences$868.45M2.18$3.20 per share10.25$15.11 per share2.17TRVITrevi TherapeuticsN/AN/AN/AN/A$1.43 per shareN/AVCELVericel$276.26M6.78$0.56 per share65.69$7.01 per share5.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-43.98%N/AHRMYHarmony Biosciences$158.69M$2.7112.108.650.4418.29%19.86%13.69%5/7/2026 (Confirmed)TRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-25.49%-24.15%N/AVCELVericel$16.52M$0.31118.6547.77N/A5.98%5.17%3.67%5/7/2026 (Estimated)Latest ADCT, HRMY, TRVI, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026HRMYHarmony Biosciences$0.76N/AN/AN/A$220.84 millionN/A5/7/2026Q1 2026VCELVericel-$0.15N/AN/AN/A$63.68 millionN/A5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/A5/4/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 million3/17/2026Q4 2025TRVITrevi Therapeutics-$0.10-$0.06+$0.04-$0.06N/AN/A3/10/2026Q4 2025ADCTADC Therapeutics-$0.32-$0.04+$0.28-$0.04$22.29 million$23.06 million2/26/2026Q4 2025VCELVericel$0.45$0.45N/A$0.45$92.66 million$92.92 million2/24/2026Q4 2025HRMYHarmony Biosciences$0.84$0.38-$0.46$0.38$240.04 million$243.78 million2/14/2026Q4 2025ADCTADC TherapeuticsN/A-$0.09N/A-$0.04N/A$23.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.374.31HRMYHarmony Biosciences0.173.603.58TRVITrevi TherapeuticsN/A19.6619.66VCELVericelN/A5.034.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%HRMYHarmony Biosciences86.23%TRVITrevi Therapeutics95.76%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%HRMYHarmony Biosciences11.00%TRVITrevi Therapeutics18.30%VCELVericel7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableHRMYHarmony Biosciences20057.87 million51.50 millionOptionableTRVITrevi Therapeutics20128.59 million105.06 millionOptionableVCELVericel30050.93 million47.06 millionOptionableADCT, HRMY, TRVI, and VCEL HeadlinesRecent News About These CompaniesWall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a BetMay 4 at 10:56 AM | zacks.comVericel Corporation (NASDAQ:VCEL) Receives $55.40 Average PT from AnalystsMay 3 at 4:47 AM | americanbankingnews.comVericel Shareholders Reaffirm Board, Pay Plan, AuditorMay 1, 2026 | tipranks.comConestoga Capital Advisors LLC Acquires 79,278 Shares of Vericel Corporation $VCELMay 1, 2026 | marketbeat.comVericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC AuditorMay 1, 2026 | marketbeat.comVericel (VCEL) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 28, 2026 | marketbeat.comVericel to Report First-Quarter 2026 Financial Results on May 7, 2026April 23, 2026 | globenewswire.comVericel (NASDAQ:VCEL) Shares Down 7.1% - Time to Sell?April 21, 2026 | marketbeat.comInsider Selling: Vericel (NASDAQ:VCEL) Insider Sells 3,472 Shares of StockApril 7, 2026 | insidertrades.comJonathan Mark Hopper Sells 3,472 Shares of Vericel (NASDAQ:VCEL) StockApril 6, 2026 | marketbeat.comAberdeen Group plc Has $21.03 Million Stock Position in Vericel Corporation $VCELApril 6, 2026 | marketbeat.comVericel Gets $197M U.S. Government Contract for Burn TreatmentApril 2, 2026 | marketwatch.comMediWound and Vericel Secure Up to $197 Million BARDA Contract for NexoBrid® Procurement and DevelopmentApril 2, 2026 | quiverquant.comQVericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBridApril 2, 2026 | markets.businessinsider.comVericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBridApril 2, 2026 | globenewswire.comWhat Makes Vericel Corporation (VCEL) an Investment Bet?March 13, 2026 | insidermonkey.comWhat Makes Vericel Corporation (VCEL) an Investment Bet?March 13, 2026 | finance.yahoo.comWill FDA Approval of Burlington MACI Manufacturing Shift Vericel's (VCEL) Long-Term Growth NarrativeMarch 10, 2026 | finance.yahoo.comVericel Corporation (VCEL) Secures FDA Approval for Commercial Manufacturing of MACIMarch 10, 2026 | msn.comVericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing FacilityMarch 4, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADCT, HRMY, TRVI, and VCEL Company DescriptionsADC Therapeutics NYSE:ADCT$3.86 +0.10 (+2.53%) Closing price 03:59 PM EasternExtended Trading$3.84 -0.01 (-0.26%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Harmony Biosciences NASDAQ:HRMY$32.78 +0.44 (+1.36%) Closing price 04:00 PM EasternExtended Trading$33.05 +0.27 (+0.82%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Trevi Therapeutics NASDAQ:TRVI$14.26 -0.40 (-2.73%) Closing price 04:00 PM EasternExtended Trading$14.26 0.00 (0.00%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Vericel NASDAQ:VCEL$36.78 -0.03 (-0.08%) Closing price 04:00 PM EasternExtended Trading$36.34 -0.45 (-1.21%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
